Cindy Whitehead, CEO of Sprout Pharmaceuticals in Raleigh holds placebo examples of her company's ADDYI (flibanserin) pink pills Wednesday, August 5, 2015. Sprout may become the first to market the pill for women with hypoactive sexual desire disorder. Sprout has completed its latest round of trials and is awaiting a ruling by the US FDA (Food and Drug Administration) on whether Sprout can take the pill to market.
Cindy Whitehead, CEO of Sprout Pharmaceuticals in Raleigh holds placebo examples of her company's ADDYI (flibanserin) pink pills Wednesday, August 5, 2015. Sprout may become the first to market the pill for women with hypoactive sexual desire disorder. Sprout has completed its latest round of trials and is awaiting a ruling by the US FDA (Food and Drug Administration) on whether Sprout can take the pill to market. Harry Lynch hlynch@newsobserver.com
Cindy Whitehead, CEO of Sprout Pharmaceuticals in Raleigh holds placebo examples of her company's ADDYI (flibanserin) pink pills Wednesday, August 5, 2015. Sprout may become the first to market the pill for women with hypoactive sexual desire disorder. Sprout has completed its latest round of trials and is awaiting a ruling by the US FDA (Food and Drug Administration) on whether Sprout can take the pill to market. Harry Lynch hlynch@newsobserver.com

Raleigh’s Sprout Pharmaceuticals awaits FDA ruling on female libido drug

August 15, 2015 06:48 PM